The IMAGINE-SPOR CIHR Chronic Disease Network (IMAGINE)

Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects: the IMAGINE-CIHR SPOR Chronic Disease Network

The IMAGINE Cohort Study will identify and recruit a cohort of 8000 patients with IBS, IBD and healthy controls (2000 of each) who will be assessed in terms of their psychological status, dietary intake, gut microbiome, metabolomic and inflammatory markers and genotype, health-related quality of life, and health care resource use and associated costs. The cohort and healthy controls will be followed prospectively for up to 5 years after the completion of study enrolment.

Study Overview

• Status: Recruiting
• Conditions: Healthy; Crohn Disease; Ulcerative Colitis; IBS - Irritable Bowel Syndrome
• Intervention / Treatment: Other: Diet; Other: Gastrointestinal microbiome

Detailed Description

The goal of the screening visit is to confirm that the Subject/Healthy Control is willing to participate in the study and that they meet the eligibility criteria for the study.

The screening visit will include:

i. Obtaining signed informed consent /assent to screen for eligibility (Consent/Assent-Subject, Consent/Assent-Control).

ii. Reviewing the subject/control for eligibility (per inclusion/exclusion criteria).

Subjects will be identified through several pathways: 1) Patients with confirmed IBS or IBD in existing site databases who have previously consented to be contacted for future IBS studies or those approached in clinic with a recent confirmed diagnosis of IBS/IBD and consent to participate and 2) patients with self-reported IBS or IBD who contact the site coordinator or who are identified in clinic with an unsubstantiated diagnosis of IBS/IBD.

Subjects with a confirmed diagnosis of IBS or IBD and who have given prior consent to be contacted, will be prescreened by phone or in person. All others will be invited to a screening visit and the study rationale and design will be explained. Interested subjects will be asked to provide informed written consent. Eligibility will then be confirmed and subjects will complete the questionnaires and provide the necessary samples at this and a follow-up visit if necessary.

Subjects who do not meet the diagnostic criteria for IBS or IBD and wish to have the diagnosis confirmed, will be advised to see their family physician for any necessary diagnostic testing. A letter to the family physician will be provided stating that the patient had been approached about the study and that the diagnosis of IBS/IBD could not been made due to an absence of testing and/or failure to meet the predefined criteria. Patients will also be informed if they fail to meet other eligibility criteria that would exclude them from the study.

When eligibility for subjects and healthy controls has been confirmed, the following questionnaires will be answered and samples obtained:

• Blood samples
• Metabolomic urine sample
• Stool sample (metagenomics, metabolomics, fecal calprotectin (FCAL) and β-defensins)
• Demographic questionnaire
• Quality of life questionnaire (EQ-5D for adults)
• Food Frequency Questionnaire
• Psychological questionnaires (pediatric for ≤ 17 years, adult for those > 17 years)
• Optional on-line additional psychological questionnaires for adults
• Disease specific questionnaires (UC, CD and IBS - UC and CD further divided into pediatric for ≤ 17 years, adult for those > 17 years)
• General gastrointestinal symptom questionnaires (Short for Leeds Dyspepsia Questionnaire, PROMIS diarrhea, PROMIS abdominal pain, PROMIS constipation and PROMIS bloating).
• Workplace productivity questionnaire.

• Study Type: Observational
• Enrollment (Anticipated): 8000

Contacts and Locations

• Study Contact: Name: Paul Moayyedi, MD; Phone Number: 76764 905-521-2100; Email: moayyep@mcmaster.ca
• Study Contact Backup: Name: Melanie AM Wolfe, CCRP; Phone Number: 73601 905-521-2100; Email: wolfe@hhsc.ca

Study Locations

• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8N 3Z5
      • Recruiting
      • Hamilton Health Sciences / McMaster University
      • Contact: Paul Moayyedi, MD; Phone Number: 76764 905-521-2100; Email: moayyep@mcmaster.ca
      • Contact: Melanie Wolfe, CCRP; Phone Number: 73601 905-521-2100; Email: wolfe@hhsc.ca
      • Principal Investigator: Paul Moayyedi, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years to 99 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

There will be 17 recruitment centres across Canada responsible for recruitment of 2000 subjects with CD, 2000 subjects with UC, 2000 subjects with IBS and 2000 healthy controls. Each centre will be required to obtain appropriate ethics approval prior to initiating study recruitment.

Description

Inclusion Criteria:

• Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire.

Exclusion Criteria:

• • major gastrointestinal surgery (Roux en y, bowel resection)

  • any major comorbid chronic condition (e.g. decompensated liver disease or malignancy, lung or cardiac disease, active HIV, diabetes mellitus requiring medication,
  • difficulties with communication or conditions affecting ability to provide informed consent,
  • unable to communicate in the language of the cohort study (English or French)
  • those who do not wish to participate in this study
  • diagnosis of schizophrenia
  • diagnosis of eating disorder

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Irritable bowel syndrome; A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study. IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated.	Other: Diet; Dietary intake; Other: Gastrointestinal microbiome; Genomic sequencing of stool for gut bacteria
Ulcerative colitis; 2000 CD and 2000 UC cases over the age of 4 years will be enrolled. Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated.	Other: Diet; Dietary intake; Other: Gastrointestinal microbiome; Genomic sequencing of stool for gut bacteria
Crohn's disease; 2000 CD cases over the age of 4 years will be enrolled. Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated.	Other: Diet; Dietary intake; Other: Gastrointestinal microbiome; Genomic sequencing of stool for gut bacteria
Healthy control; A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study. Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated.	Other: Diet; Dietary intake; Other: Gastrointestinal microbiome; Genomic sequencing of stool for gut bacteria

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IMAGINE microbiome and diet	Microbiome and dietary comparison between UC, CD, IBS and controls predictors of failure of therapy (each class of therapy in UC, CD, IBS and each disease will be analyzed separately)	baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IMAGINE metabolomics	Metabolomic comparison between UC, CD, IBS and controls	baseline and five years
IMAGINE anxiety	Anxiety score evaluated using PROMIS questionnaire between UC, CD, IBS and controls	baseline and five years
IMAGINE depression	Depression score evaluated using PROMIS questionnaire between UC, CD, IBS and controls	baseline and five years
IMAGINE health related costs	Health related costs measured by provincial databases and questionnaire between UC, CD, IBS and controls	baseline and five years
IMAGINE microbiome and diet	Microbiome and dietary comparison between UC, CD, IBS and controls	five years

Collaborators and Investigators

• Sponsor: Hamilton Health Sciences Corporation
• Collaborators: Canadian Institutes of Health Research (CIHR)
• Investigators: Principal Investigator: Paul Moayyedi, MD, HHSC

Publications and helpful links

General Publications

• Moayyedi P, MacQueen G, Bernstein CN, Vanner S, Bercik P, Madsen KL, Surette M, Rioux JD, Dieleman LA, Verdu E, de Souza RJ, Otley A, Targownik L, Lavis J, Cunningham J, Marshall DA, Zelinsky S, Fernandes A. IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open. 2020 Oct 21;10(10):e041733. doi: 10.1136/bmjopen-2020-041733.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2017
• Primary Completion (Anticipated): December 1, 2022
• Study Completion (Anticipated): June 1, 2023

Study Registration Dates

• First Submitted: March 10, 2017
• First Submitted That Met QC Criteria: April 24, 2017
• First Posted (Actual): April 27, 2017

Study Record Updates

• Last Update Posted (Actual): March 16, 2022
• Last Update Submitted That Met QC Criteria: March 15, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Disease Attributes; Gastrointestinal Diseases; Gastroenteritis; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Inflammatory Bowel Diseases; Irritable Bowel Syndrome; Chronic Disease; Crohn Disease
• Other Study ID Numbers: REB#3000

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No